LB P2D
Alternative Names: LB-P2DLatest Information Update: 20 Jun 2022
At a glance
- Originator LISCure Biosciences
- Developer LISCure Biosciences; The Scripps Research Institute
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 20 Jun 2022 LISCure Biosciences plans a phase I trial for Solid tumours (Late-stage disease), in 2022 (LISCure Biosciences pipeline, June 2022)